 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023 SZN-1326 Phase 1a clinical trial in healthy volunteers continues to enroll with safety data expected by the end of 2023 Corporate ...

Surrozen Provides Second Quarter 2023 Financial Results

In a preclinical model of ischemic stroke, systemic delivery of a selective Fzd4 Wnt antibody strongly reduced blood-brain-barrier leakage, death of surrounding brain tissue, tissue swelling, while improving neurologic scoreResults highlight potential of selective Fzd4 Wnt antibody for central ...

Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke

Surrozen (NASDAQ:SRZN Get Rating) and SAB Biotherapeutics (NASDAQ:SABS Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, ...

Contrasting Surrozen (NASDAQ:SRZN) & SAB Biotherapeutics (NASDAQ:SABS)

Surrozen: Q1 Earnings Insights

Enrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety data expected by the end of 2023 Enrollment ongoing in SZN-1326 Phase 1a clinical trial in healthy volunteers with safety data expected by the end of 2023 SOUTH SAN ...

Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates

Surrozen, Inc. (NASDAQ:SRZN  Get Rating) was the recipient of a large decline in short interest in the month of April. As of April 15th, there was short interest totalling 350,500 shares, a decline of 17.3% from the March 31st total of 424,000 shares. Based on an average trading volume of 501...

Surrozen, Inc. (NASDAQ:SRZN) Short Interest Update

SOUTH SAN FRANCISCO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Surrozen, Inc. (Surrozen or the Company) (Nasdaq: SRZN), a company pioneering targeted therapeutics that selectively activate the Wnt pathway for tissue repair and regeneration, today announced that Eric Bjerkholt has been appointed to ...

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

Surrozen (NASDAQ:SRZN  Get Rating) and CEL-SCI (NYSE:CVM  Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, profitability, valuation, risk, dividends, analyst recommendations ...

Financial Survey: Surrozen (NASDAQ:SRZN) versus CEL-SCI (NYSE:CVM)

Surrozen, Inc. (NASDAQ:SRZN Get Rating) saw a significant decrease in short interest in March. As of March 15th, there was short interest totalling 380,300 shares, a decrease of 23.6% from the February 28th total of 497,900 shares. Currently, 2.2% of the shares of the stock are sold short. Based on ...

Surrozen, Inc. (NASDAQ:SRZN) Short Interest Down 23.6% in March

Enrolled first patient in SZN-043 Ph 1a clinical trial in chronic liver disease with data expected by the end of 2023 Expect to begin SZN-043 Ph1b clinical trial in severe alcoholic hepatitis in 2024 with proof-of-concept data expected in the second half of 2024 Expect to reinitiate SZN-1326 Ph1a ...

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

Surrozen, Inc. is a clinical stage biotechnology company. It engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company was founded by K. Christopher Garcia and Roeland Nusse on August 12, 2015 and is headquartered in South San Francisco, CA.

Watchers	1,251
52-Wk Low	$0.3434
52-Wk High	$2.84

Market Cap	$14.34M
Volume (M)	19,108.00
52-Wk High	$2.84
52-Wk Low	$0.3434

SRZN Surrozen Inc

About

Feed

News

Sentiment

Earnings

Fundamentals